Abstract: Azilsartan (AZL) medoxomil was approved by the United States Food and Drug Administration in 2011 for the treatment of hypertension and has shown promising results both in blood pressure (BP) reduction and in tolerability, but has not yet been taken into practice to the same extent as other angiotensin II receptor blockers (ARBs) that have been on the market for a longer period. AZL antagonizes the AT 1 receptor for angiotensin II (ANG II), whereas angiotensin-converting enzyme inhibitors block the conversion of angiotensin I to ANG II, but not alternative routes of formation of ANG II. The bioavailability of AZL is about 60% and it has a t max of 1.5-3 hr and a half-life of approximately 11 hr. With its IC 50 of 7.4 nM after 5 hr of drug washout in radioligand assays, AZL has a tighter and longer-lasting binding to the AT 1 receptor by several orders of magnitude than other ARBs, which might lead to a more effective reduction in BP. Clinical studies have revealed that AZL doses of 40 and 80 mg/day reduce BP significantly better than maximal clinical doses of valsartan or olmesartan, while being well tolerated and exhibiting a spectrum of adverse effects comparable to those of other ARBs. These properties of AZL might lower the risk of cardiovascular disease and thereby reduce mortality rates. However, the existing mortality studies have not found this correlation, which should be further investigated.
Hypertension is defined by the international hypertension societies and by the World Health Organization (WHO) and can be categorized into several stages. An exact threshold value is difficult to establish and subject to change over time, but currently, most guidelines have defined a BP of >140/90 mmHg as requiring treatment. This value is lower for patients with other risk factors, for instance diabetes mellitus and kidney disease [1] . In 2004, the prevalence of hypertension was estimated to affect approximately 30% of the population on a global scale [2] . These numbers are even higher for some countries, including Denmark, where the prevalence of hypertension is found to be nearly 40%, and of these, only 60% of the patients are aware of their diagnosis [3] . Hypertension is a major risk factor for cardiovascular disease and mortality worldwide.
Hypertension is known as an important risk factor for cardiovascular disease. It leads to a higher risk of ischaemic heart disease, angina pectoris, acute myocardial infarction, heart failure, arteriosclerosis, cerebral thrombosis, stroke and kidney disease [4] . The increased risk is present in all age groups, and for every 20-mmHg increase in systolic or 10-mmHg increase in diastolic pressure, the risk of ischaemic heart disease and stroke is doubled [5] . The Framingham Heart Study found that an elevated BP (130-139 mmHg systolic and 85-89 mmHg diastolic) doubles the risk of cardiovascular disease compared with those with a BP below 120/80 mmHg [6] . The risks associated with hypertension can be reduced by lowering BP by both lifestyle intervention and antihypertensive therapy. Even small changes in BP influence the risk of cardiovascular disease. Therefore, an effective treatment is of great importance to prevent cardiovascular conditions in the large group of patients suffering from hypertension.
Beside antihypertensive drugs such as thiazide diuretics, badrenoceptor antagonists (BAA) and calcium channel blockers, which have an effect on blood volume, heart rate and vasodilation, respectively [7] [8] [9] , an important therapeutic approach for hypertension is the blockade of the renin-angiotensin-aldosterone system (RAAS). Azilsartan (AZL) was recently introduced for treatment of hypertension mainly due to unprecedented tight binding to the angiotensin receptor, AT 1 , and the pharmacokinetic and testing in animal studies as well as a proposed role in the human clinic have recently been reviewed [10] [11] [12] . Here, we have focused on the strong interaction of the drug with the AT 1 receptor and whether that is reflected in the clinical effects of the drug and compared with other angiotensin receptor antagonists.
Literature Search
The data presented in this MiniReview were gathered by searches in online repositories such as PubMed (http://www. Author for correspondence: Daniela G. Grimm, Department of Biomedicine, Pharmacology, Aarhus University, Wilhelm Meyers All e 4, DK-8000 Aarhus C, Denmark (e-mail dgg@biomed.au.dk).
pubmed.com), EMBASE (http://www.embase.com) and clinicaltrials.gov (http://www.clinicaltrials.gov) using search terms like "azilsartan," "hypertension," "angiotensin receptor blocker" and every possible permutation and combination. A total of 139 articles from PubMed and 386 from EMBASE, respectively, were collected and surveyed for suitability for this review. Clinical trials have been covered from 2011 until 30 March 2017.
The Renin-Angiotensin-Aldosterone Axis
The renin-angiotensin-aldosterone axis is a blood-borne cascade signalling system that reacts to decreases in effective circulating volume. Renin is a protease that cleaves angiotensinogen, produced by the liver, to angiotensin I (ANG I). ANG I is then cleaved by the angiotensin-converting enzyme (ACE) to angiotensin II (ANG II) [6] .
ANG II binds to two different G-protein-coupled receptors, the AT 1 and AT 2 receptors (AT2R). The AT 1 receptor is more abundant and is found in many organs and tissues, such as vessels, the brain, the heart, the kidneys, the adrenal glands and nerve terminals.
ANG II signalling via the AT 1 receptor leads to several effects, all aiming to increase the BP. ANG II leads to systemic vasoconstriction causing an increased pre-and afterload of the heart. In the kidneys, ANG II has a direct effect on the Na + reabsorption in the proximal tubule and increased vasopressin release leads to an increase in water reabsorption. ANG II also stimulates thirst [13, 14] . The AT2R is mainly present during the foetal development and its expression is up-regulated in pathological conditions such as atherosclerosis. Furthermore, activation of AT2R can exert an end-organ-protective anti-inflammatory effect [15] [16] [17] [18] .
Interestingly, over the last years, new players in the RAAS have been identified. ANG (1-7), long believed to be a mostly inactive ANG I metabolite [19] , was shown to be cleaved from ANG II by the angiotensin-converting 2 enzyme (ACE2), and to be an agonist of the G-protein-coupled receptor Mas [20] [21] [22] . Via Mas, ANG (1-7) exerts a vasodilatory effect through NO release [23] . Furthermore, it has antifibrotic effects and seems to have opposite effects to those of ANG II by counteracting cell growth [24, 25] .
The prorenin/renin/MAP kinase pathway recently emerged as another RAAS pathway. Prorenin and/or active renin can bind to the (pro)renin receptor ((P)RR), activating the ERK1/2 axis and leading to an increased production of TGF-b, which promotes tissue fibrosis [26, 27] . As RAAS blockade causes a rise in plasma renin and prorenin levels, it was suggested that the (P)RR might therefore be connected to the increased risk of cardiovascular death in patients undergoing haemodialysis and receiving dual ACE-I and ARB therapy in comparison with those in treatment with only one RAAS blocker [28, 29] .
Antagonizing the RAAS will lower the BP. This principle is exploited in several classes of antihypertensive drugs ( fig. 1 ): direct renin inhibitors, for example aliskiren, compete with endogenous angiotensinogen for the binding to renin.
ACE inhibitors (ACE-I) are inhibiting the conversion of ANG I to ANG II. Aldosterone antagonists reduce water reabsorption. AT 1 receptor antagonists directly block the AT 1 receptor so that ANG II cannot bind to it.
The AT 1 Receptor/ARBs Mechanism of Action
The main signalling pathways of the AT 1 receptor are shown in fig. 2 . Binding of ANG II leads to the activation of phospholipase C, which converts phosphatidylinositol 4,5-bisphosphate (PIP 2 ) to inositol triphosphate (IP 3 ) and diacylglycerol (DAG). IP 3 binds to the endoplasmic reticulum whereas DAG activates protein kinase C (PKC). Further, the AT 1 receptor stimulates G-protein-independent signalling pathways, such as Jak/STAT [30, 31] . Binding of ANG II also enhances proliferation and cell survival via transactivation of the epidermal growth factor receptor (EGFR) and the platelet-derived growth factor (PDGF) and the phosphatidylinositol 3-kinase (PI3K)/ Akt pathway or extracellular signal-regulated kinase (ERK) pathway, respectively [32, 33] . In summary, these effects lead to a general vasoconstriction, increased release of aldosterone leading to increased Na + and water reabsorption, as well as to cell proliferation in the heart and arteries. An increased release of catecholamines from the adrenal causes an increased sympathetic activity [3] . Furthermore, the AT 1 receptor is also indirectly implicated in the ANG II activation of mineralocorticoid receptor-mediated gene expression in human vascular smooth muscle cells, leading to an increased expression of genes involved in inflammation, fibrosis and calcification. This activation was abolished by the ARB losartan, indicating that ANG II exerts its effect on the mineralcorticoid receptor via a signalling cascade involving the AT 1 receptor [34] . Angiotensin II receptor blockers antagonize the AT 1 receptor with more than 10,000-fold selectivity for the AT 1 receptor compared to the AT2R. They antagonize the hypertensive effects of ANG II but leave the AT2R open for activation. ACE-I inhibits the formation of ANG II but does not block ANG II formation by alternative routes, for example chymase. ARBs will block the effect of ANG II irrespective of its synthesis pathway. This mechanism provides a more selective blockage of the ANG II effects through the AT 1 receptor and preserves the more favourable anti-inflammatory effects of the AT2R.
ACE-I also blocks the degradation of bradykinin, leading to dry cough, a known side effect of ACE-I. ARBs do not have this effect as the ACE is still functioning [35] .
Azilsartan
Azilsartan medoxomil ( fig. 3 ) is the 8 th sartan developed since the first ARB losartan potassium was approved by the United States Food and Drug Administration (FDA) in 1995 [36] . AZL medoxomil was approved by the FDA in February 2011 [37] . AZL is a selective AT 1 receptor antagonist that only antagonizes the AT 1 but not the AT2R. Thereby, it mediates vasodilatation, reduces aldosterone release and reduces sympathetic stimulus of vessels and kidney [38] .
Azilsartan Pharmacokinetic and Pharmacodynamic Properties
Azilsartan medoxomil is a prodrug that is hydrolysed in the intestines to the active component AZL. AZL has a t max of 1.5-3 hr and its bioavailability is approximately 60%. The drug is degraded by cytochrome P450 (2C9) to an inactive metabolite that is excreted primarily by the kidney. AZL has a half-life of approximately 11 hr [38, 39] . There are seven other ARBs on the market: losartan, olmesartan (OLM), valsartan (VAL), candesartan, telmisartan, irbesartan and eprosartan. In comparison with other commonly used ARBs, AZL exhibits a greatly increased binding affinity to the AT 1 receptor and a strong selectivity of 10,000:1 for AT 1 versus AT2Rs. Especially after a 5-hr drug washout period, IC 50 values for AZL were lower by one to three orders of magnitude than those of OLM, telmisartan, irbesartan or VAL, as shown by in vitro radioligand binding and inositol 1-phosphate accumulation measured in cultured COS-7 cells [37, 40] (table 1) .
Adverse Effects
The most common adverse effects (AE) experienced when treated with ARBs are headache, dizziness, urinary tract infection and dyslipidaemia. Changes in serum creatinine, potassium and liver enzyme levels, indicating reduced kidney function or even, in more serious cases, kidney failure, and impairment of liver function, respectively, are also found in patients treated with ARBs. However, several studies have been conducted suggesting that AZL is not associated with a significant increase in AE, compared to other ARBs or placebo groups, reflecting a generally well-tolerated drug class [41] [42] [43] . The ONTARGET study compared the ACE inhibitor ramipril to the ARB telmisartan and found that AE such as cough and angioedema were less frequent during ARB therapy, but hypotensive symptoms were seen more frequently with telmisartan (but not syncopes). The hypotensive symptoms could be explained by the fact that telmisartan was more effective in lowering BP than ramipril [44] .
B€ onner et al. [45] compared AZL to ramipril and found that cough, which is a common side effect of ACE inhibitors, was less frequent during treatment with AZL. Discontinuation from the treatment was also less frequent in the AZL group. The study found higher rates of dizziness with AZL. Sica et al. [ 43] found that an increase in serum creatinine was slightly more frequent with AZL than with VAL [43, 45] .
Clinical Trials with Azilsartan
Azilsartan medoxomil was tested in several clinical trials (table 2) . In most of these trials, AZL was compared to other ARBs and placebo groups. AZL was found to be superior in its BP-lowering effects and was well tolerated with similar AE to placebo or the comparative drug [41] [42] [43] [45] [46] [47] [48] .
Azilsartan Compared to ACE-I
Azilsartan is a relatively new drug, and this review aims to enlighten whether the addition to the ARB group in 2011 is worth considering. The articles addressed in this review have all shown that AZL is superior in lowering BP, compared to both ACE inhibitors and other ARBs [41] [42] [43] 49] . In the EARLY register study, the BP-lowering effect, the safety profile and the AE of AZL were investigated and compared to those of ACE inhibitors. The adjusted systolic blood pressure (SBP)-lowering effect for AZL was 25.3 mmHg in patients receiving no antihypertensive treatment prior to enrolment in the study. In the group receiving ACE-I, a mean SBP reduction of 24 mmHg was recorded, which leaves a difference between the two drugs of 1.3 mmHg (p < 0.001). Even though this is no big difference, a significantly higher percentage of the patients treated with AZL reached a BP below 140/90 mmHg (61.7% with AZL and 55.5% with ACE-I). This showed that AZL more effectively lowered BP and resulted in a better compliance [50] . Similar results were found in the clinical trial conducted by B€ onner et al. [45] . Using clinical BP measuring, a mean SBP reduction by 21.2 mmHg was found in the group treated with AZL and a significantly less pronounced reduction by 12.2 mmHg (p < 0.001) was detected in the group treated with the ACE-I ramipril. However, the study also conducted a 24-hr BP monitoring, where the reductions in SBP were found to be 12.3 mmHg in the AZL group and 7.8 mmHg in the ramipril group, leaving a difference of 4.5 mmHg between the two groups [45] . This indicated that the choice of BP measurement method can influence the results of the studies. B€ onner et al. [45] also found that fewer patients treated with AZL developed cough as an AE compared to the group treated with ramipril. However, higher rates of hypotension and dizziness were reported in the group treated with AZL. AE-related discontinuation occurred less frequently in the groups treated with AZL, reflecting a better compliance. This claim is supported by Elliot et al. [51] , who found that ARB in general lead to a better compliance than in other classes of antihypertensive drugs.
The difference between the BP-lowering effects may be due to the difference in the mechanism of action between ACE-I and ARBs. ACE-I only prevents the ACE-mediated ANG I to ANG II conversion, whereas ANG II production by alternative routes is unchanged, while bradykinin levels are increased by Table 1 .
Pharmacokinetic properties of the ARBs currently on the market, modified from [30] . ACE-I. ARBs, on the other hand, directly inhibit the interaction of all ANG II with the AT 1 receptor, irrespective of the actual source of ANG II [39] . Even though studies found that ARBs are more effective in reducing the BP and that the compliance might be greater, there is still no evidence that the mortality rates for ARBs are better than for ACE-I. Li et al. and Reboldi et al. [52, 53] reported that there is no difference between the total mortality, cardiovascular events or the cardiovascular mortality for ARBs versus ACE-Is. Sica et al.
[43] compared 24-hr mean SBP in groups treated with either 40 or 80 mg AZL versus 320 mg VAL. The study found that AZL reduced SBP by À14.9 and À15.3 mmHg at 40 and 80 mg doses, respectively. Treatment with VAL reduced 24-hr SBP by 11.3 mmHg. They also showed that an increase in serum creatinine occurred more often in the AZL group, but the AE were similar in the three groups [43] .
The three studies found AZL to be superior in lowering BP in its clinical maximum dosage, compared to other ARBs. The difference between the ARBs may be caused by a more potent inhibitory effect on the AT 1 receptor of AZL, and a tighter and longer-lasting binding to the receptor [39, 51] . This could produce a more potent and longer-lasting BP reduction [40, 54] . Even though White et al. [41] , Bakris et al. [42] and Sica et al. [43] found that the difference between AZL and the other ARBs is small (2.1-4.4 mmHg), even small changes in BP decrease the risk of cardiovascular complications. A 2-mmHg decrease in SBP lowers stroke mortality by 10% and ischaemic heart disease mortality by 7% [55] . However, these decreased risks are not seen in the mortality studies [52, 53] . This may be because the mortality studies are not of sufficient size and design to properly evaluate the mortality rates -for instance, none have been compared to placebo.
Discussion and Conclusion
In several clinical trials, AZL medoxomil has proven to be effective in lowering BP and thereby reducing the risk of cardiovascular disease. AZL has been compared to other ARBs and to ACE-I, both antagonizing the RAAS system, and was found to be superior in its BP-lowering effect at its highest clinical doses. Some studies found a greater difference between the treatment options than others but all found a significantly greater BP reduction in treatment with AZL, compared to that of other ARBs and ACE-I.
Azilsartan medoxomil was well tolerated, and AE were proven to be the same for other ARBs and for placebo. A significantly higher compliance was found in the groups treated with AZL compared to those treated with ACE-I. An issue in treatment with ACE inhibitors has been the development of dry cough, caused by the inhibition of bradykinin degradation. This adverse effect is found less frequent in AZL therapy, as ARBs do not interfere with the action of ACE but only block the AT 1 receptor for ANG II.
The greater reduction in BP and better compliance found in AZL-treated patients is believed to reduce the risk of cardiovascular disease and mortality. However, these positive effects were not detected in the mortality studies where ARBs have been compared to ACE-I. The reason for this finding could be that the mortality studies were not of a sufficient size and design to evaluate the long-term outcome of treatment with ARBs. Overall, a recent review analysing the currently available data on AZL treatment concluded that "AZL is a safe and effective treatment option for every stage of hypertension, both alone or in fixed-dose combination tablets with chlorthalidone or amlodipine" [56] .
Outlook
Hypertension continues to be a major health issue, even among already diagnosed patients. Only some patients with hypertension treatment reach a BP below the recommended value. This calls for not only more effective drugs, but in addition, it should be examined why some patients exhibit a low compliance to treatment.
Azilsartan medoxomil was approved by the FDA in 2011, and it has been found to be an effective drug against hypertension. Clinical trials concluding that AZL is more effective in lowering BP gives rise to a better compliance to treatment and has the same or fewer side effects as other treatment options such as ACE-I and other ARBs. AZL was found not to cause dry cough, which is a problematic side effect of the widely used ACE-I. There is basis for future studies investigating mortality rates between ARBs in general and other antihypertensive treatment options, to determine whether ARBs are superior in reducing mortality rates in the long run.
